Last reviewed 2026-04-23 · How we verify

V114

V114 is a recombinant vesicular stomatitis virus (VSV) vector-based vaccine that expresses the SARS-CoV-2 spike protein.

V114 is a recombinant vesicular stomatitis virus (VSV) vector-based vaccine that expresses the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.

At a glance

Mechanism of action

This vaccine is designed to stimulate an immune response against the SARS-CoV-2 virus, with the goal of preventing infection and disease. The VSV vector is used to deliver the spike protein to immune cells, where it is processed and recognized as foreign, triggering an immune response.

Approved indications

• Prevention of COVID-19

Common side effects

• Pain, redness, swelling, or itching at the injection site

Key clinical trials

• V114 and Acute Otitis Media (V114-032/PNEU-ERA) (PHASE3)
• Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (PHASE3)
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) (PHASE1)
• Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) (PHASE3)
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) (PHASE3)
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) (PHASE3)
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PHASE3)
• A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.